Ranked No. 1! NeuDirection Wins “Excellence Award” at the 16th Moorden Institute Accelerator Pitch Day

On April 29, 2026, the 16th Accelerator Pitch Day, hosted by Moordn Institute in collaboration with leading partner institutions, was successfully held in Guangzhou. The event brought together more than 50 representatives from investment and financial institutions, alongside over 100 entrepreneurs and industry leaders from the Greater Bay Area, showcasing some of the region’s most promising innovation-driven ventures. Against this competitive backdrop, NeuDirection emerged as the top-ranked company of the event. Following a rigorous evaluation process and live scoring by an expert panel, the company achieved the highest overall score among all presenting teams and was awarded the event’s top…

NeuDirection’s Neu-001 Successfully Completes Phase I Clinical Trial

NeuDirection announces that its innovative drug Neu-001 for the treatment of amblyopia has successfully completed its Phase I clinical trial. The trial results demonstrated favorable safety and tolerability profiles, establishing a solid foundation for further clinical development. Neu-001 is a highly selective GPCR agonist capable of crossing the blood-brain barrier. By activating neuroplasticity in the visual cortex, it offers a potential new pharmacological approach for adult amblyopia patients. Current amblyopia treatment relies primarily on patching therapy during childhood, leaving adult patients with limited effective options. Neu-001 has the potential to address this unmet clinical need. The Phase I clinical trial…

Groundbreaking Discovery in Cell: NeuDirection Limited’s Lead Asset Neu-001 Demonstrates New Potential for Alzheimer’s Disease Treatment

NeuDirection Limited has achieved a significant scientific breakthrough with its lead asset, Neu-001, in the field of Alzheimer’s disease (AD) treatment. On January 22, 2026, an independent study published online in the prestigious international journal Cell revealed the novel potential of Neu-001 in treating Alzheimer’s disease. Alzheimer’s disease (AD) is the most common neurodegenerative disorder globally, affecting tens of millions of patients and their families. Despite significant progress in understanding disease mechanisms in recent years, there remains a critical scarcity of effective therapeutic drugs. On January 22, 2026, Cell published a research paper titled “Elucidating pathway-selective biased CCKBR agonism for…

Successful Dosing of First Subject in Phase I Clinical Trial for our First-in-Class Amblyopia Drug, Neu-001

NeuDirection Limited (“NeuDirection”) announced that the first healthy subject has been successfully dosed in the Phase I clinical trial for its lead pipeline candidate, Neu-001, a first-in-class small molecule drug for the treatment of amblyopia. The first dose was administered on August 30, 2025, at Shanghai General Hospital. This study aims to evaluate the safety, tolerability, and pharmacokinetic profile of Neu-001 in healthy adults, providing critical data for subsequent clinical development. The Phase Ia clinical trial of Neu-001 is a single-center, randomized, double-blind, placebo-controlled, Single Ascending Dose (SAD) study. The study plans to enroll 53 healthy adult subjects to be…